Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 21Isotretinoin 14Etoposide 13Topotecan 12Irinotecan 12dinutuximab 10Temozolomide 10Magnetic Resonance Spectroscopy 10Doxorubicin 10Melphalan 9sargramostim 8Vincristine 8Filgrastim 7Cisplatin 7Specimen Handling 6Granulocyte-Macrophage Colony-Stimulating Factor 6Granulocyte Colony-Stimulating Factor 6Carboplatin 63-Iodobenzylguanidine 6X-Rays 5Phantoms, Imaging 5Busulfan 5Biopsy 5fludarabine 4etoposide phosphate 4aldesleukin 4Thiotepa 4Stem Cell Transplantation 4Radiotherapy 4Nuclear Medicine Department, Hospital 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroblastoma × Fenofibrate × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡